Literature DB >> 17488654

Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3.

Ann De Becker1, Paul Van Hummelen, Marleen Bakkus, Isabelle Vande Broek, Joke De Wever, Marc De Waele, Ivan Van Riet.   

Abstract

BACKGROUND AND OBJECTIVES: Mesenchymal stem cells (MSC) are adult stem cells that can be expanded many fold in vitro and have the therapeutic potential to restore the bone marrow microenvironment and support hematopoietic recovery after myeloablative conditioning for hematopoietic stem cell transplantation. Successful homing to the target tissue, such as bone marrow, implies that MSC are able to extravasate after systemic administration. However, the extravasation capacity of MSC and the underlying mechanisms are poorly understood to date. We studied in vitro the capacity of MSC to migrate through bone marrow endothelium. DESIGN AND METHODS: In vitro invasion and transendothelial migration assays were performed. The expression of matrix metalloproteinase (MMP) was analyzed by reverse transcriptase polymerase chain reaction (RT-PCR) and zymography. Migration of cells cultured at high or low confluence was compared and differential gene expression in these conditions was analyzed with microarray and real-time RT-PCR. The functional involvement in MSC migration was assessed using neutralizing anti-MMP-2 antibody, MMP-2 short interfering RNA or recombinant tissue inhibitor of metalloproteinase (TIMP-3).
RESULTS: We demonstrated that MSC can invade reconstituted basement membrane and that bone marrow endothelial cells stimulate this process. We also showed that the transendothelial migration of MSC is at least partially regulated by MMP-2. High culture confluence was found to increase production of the natural MMP-inhibitor TIMP-3 and decrease transendothelial migration of MSC. INTERPRETATION AND
CONCLUSIONS: We show that MSC have the potential to migrate through bone marrow endothelium and that this process involves MMP-2. Moreover, the migration of MSC is significantly influenced by the level of culture confluence. Increased culture confluence impairs migration and is related to an upregulation of TIMP-3. The therapeutic use of MSC would benefit from a selection of culture conditions that allow optimal extravasation of these cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17488654     DOI: 10.3324/haematol.10475

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  82 in total

1.  Homing of Mesenchymal Stem Cells.

Authors:  Reinhard Henschler; Erika Deak; Erhard Seifried
Journal:  Transfus Med Hemother       Date:  2008-07-21       Impact factor: 3.747

Review 2.  Mesenchymal stem cells: Mechanisms of immunomodulation and homing.

Authors:  Hiroshi Yagi; Alejandro Soto-Gutierrez; Biju Parekkadan; Yuko Kitagawa; Ronald G Tompkins; Naoya Kobayashi; Martin L Yarmush
Journal:  Cell Transplant       Date:  2010-06-03       Impact factor: 4.064

Review 3.  Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton.

Authors:  Diptiman Chanda; Sanjay Kumar; Selvarangan Ponnazhagan
Journal:  J Cell Biochem       Date:  2010-10-01       Impact factor: 4.429

4.  Proteomic Profiling of Native Unpassaged and Culture-Expanded Mesenchymal Stromal Cells (MSC).

Authors:  Erika Moravcikova; E Michael Meyer; Mirko Corselli; Vera S Donnenberg; Albert D Donnenberg
Journal:  Cytometry A       Date:  2018-09-13       Impact factor: 4.355

Review 5.  Regulatory factors of mesenchymal stem cell migration into injured tissues and their signal transduction mechanisms.

Authors:  Li Li; Jianxin Jiang
Journal:  Front Med       Date:  2011-03-17       Impact factor: 4.592

6.  Corticosterone mediates the inhibitory effect of restraint stress on the migration of mesenchymal stem cell to carbon tetrachloride-induced fibrotic liver by downregulating CXCR4/7 expression.

Authors:  Shanshan Zhang; Chuan Lv; Xue Yang; Zhipeng Han; Shuili Zhang; Jianwei Zhang; Chen Zong; Lu Gao; Li Li; Qiudong Zhao; Rong Li; Yang Yang; Fenghai Yu; Xiaoning Li; Ping Zhang; Lixin Wei
Journal:  Stem Cells Dev       Date:  2014-11-11       Impact factor: 3.272

Review 7.  Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases.

Authors:  Robert D Wyse; Gary L Dunbar; Julien Rossignol
Journal:  Int J Mol Sci       Date:  2014-01-23       Impact factor: 5.923

Review 8.  The potential role of stem cells in the treatment of urinary incontinence.

Authors:  Christine Tran; Margot S Damaser
Journal:  Ther Adv Urol       Date:  2015-02

9.  Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts.

Authors:  Paola Secchiero; Sonia Zorzet; Claudio Tripodo; Federica Corallini; Elisabetta Melloni; Lorenzo Caruso; Raffaella Bosco; Sabrina Ingrao; Barbara Zavan; Giorgio Zauli
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

10.  Matrix metalloproteinase 1 is necessary for the migration of human bone marrow-derived mesenchymal stem cells toward human glioma.

Authors:  Ivy A W Ho; Kelly Y W Chan; Wai-Hoe Ng; Chang M Guo; Kam M Hui; Philip Cheang; Paula Y P Lam
Journal:  Stem Cells       Date:  2009-06       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.